A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.

A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin's lymphomas for over 20 years, but several newer regimens, referred to as second or third generation, have been reported to give improved res...

Descripción completa

Detalles Bibliográficos
Autores principales: Linch, D. C., Vaughan Hudson, B., Hancock, B. W., Hoskin, P. J., Cunningham, D. C., Newland, A. C., Milligan, D. W., Stevenson, P. A., Wood, J. K., MacLennan, K. A., Anderson, L., Gregory, W. M., Vaughan Hudson, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074593/
https://www.ncbi.nlm.nih.gov/pubmed/8688344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074593/
https://www.ncbi.nlm.nih.gov/pubmed/8688344

Ejemplares similares